logo-loader
viewBiocept Inc

Biocept partners with California physician association to provide cancer testing

Biocept will offer the association an array of cancer-detection tools to help its physicians cater to their patients

Biocept Inc -
Headquartered in San Diego, Biocept is a diagnostics company which offers assays to detect lung, breast, gastric, colorectal and prostate cancers as well as melanoma

Biocept Inc (NASDAQ:BIOC), a provider of liquid biopsy tests, has struck up an agreement with an undisclosed independent physician association in California to provide liquid biopsy testing services to its physicians and patients. 

As part of the tie-up, Biocept will offer the association an array of cancer-detection tools such as biomarker tests as well as a liquid biopsy panel to help its physicians cater to their patients.

READ: Biocept wins US Patent for its liquid biopsy cancer testing technology; shares jump

“Now, more people in California will have access to our Target Selector liquid biopsy testing services, which can help physicians identify actionable biomarkers in patients diagnosed with cancer and design personalized treatment programs in order to improve outcomes,” said Michael Nall, Biocept’s CEO.

Headquartered in San Diego, Biocept is a diagnostics company which offers assays to detect lung, breast, gastric, colorectal and prostate cancers as well as melanoma. Its flagship Target Selector technology platform collects and analyzes molecular markers linked to tumors in circulating tumor cells as well as plasma to identify cancer mutations.

Quick facts: Biocept Inc

Price: 0.4181 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $54.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Biocept reveals double-digit revenue jump and new Target Selector molecular...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive how the California-based company saw revenue jump by double-digits in its fiscal first quarter despite headwinds from the coronavirus pandemic. What's more, Nall says the developer of liquid biopsy tests has released a new Target...

2 days, 5 hours ago

2 min read